Novo Nordisk A/S
CSE:NOVO B

Watchlist Manager
Novo Nordisk A/S Logo
Novo Nordisk A/S
CSE:NOVO B
Watchlist
Price: 309.6 DKK 1.24% Market Closed
Market Cap: 1.4T DKK

Novo Nordisk A/S
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Novo Nordisk A/S
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Novo Nordisk A/S
CSE:NOVO B
Cash & Cash Equivalents
kr32.1B
CAGR 3-Years
4%
CAGR 5-Years
5%
CAGR 10-Years
8%
H Lundbeck A/S
CSE:HLUN A
Cash & Cash Equivalents
kr4.7B
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ALK-Abello A/S
CSE:ALK B
Cash & Cash Equivalents
kr666m
CAGR 3-Years
44%
CAGR 5-Years
30%
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Cash & Cash Equivalents
kr1.4m
CAGR 3-Years
-51%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
No Stocks Found

Novo Nordisk A/S
Glance View

In the heart of Denmark, Novo Nordisk A/S stands as a beacon of innovation in the pharmaceutical industry, tracing its roots back to the early 20th century when it began as a small insulin-producing laboratory. This company, now a global heavyweight, is renowned for its dedication to diabetes care, a commitment that has driven its meteoric rise. Novo Nordisk's operations are deeply entrenched in the discovery, development, and production of medicines aimed at treating chronic diseases such as diabetes, obesity, and rare blood and endocrine disorders. Their prowess in biotechnology is not only evident in their diverse product portfolio but also in their relentless pursuit of new therapeutics through cutting-edge research and development, underscoring their mantra of improving the quality of life for millions across the globe. At its core, Novo Nordisk's business model is a sophisticated blend of patient-centric innovation and strategic market outreach. Sales of insulin and GLP-1 receptor agonists form the backbone of their revenue, targeting a growing global demographic faced with diabetes and related metabolic conditions. Their manufacturing process is a finely-tuned system that transforms complex scientific discoveries into tangible, effective treatments. Through strategic pricing, partnerships, and expansion in both mature and emerging markets, Novo Nordisk skillfully maneuvers the intricate web of global healthcare demands. By leveraging a robust pipeline of new drugs and improving access to existing therapies, the company not only secures its financial health but also ensures that its impact on healthcare remains profound and far-reaching.

NOVO B Intrinsic Value
483.46 DKK
Undervaluation 36%
Intrinsic Value
Price

See Also

What is Novo Nordisk A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
32.1B DKK

Based on the financial report for Sep 30, 2025, Novo Nordisk A/S's Cash & Cash Equivalents amounts to 32.1B DKK.

What is Novo Nordisk A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
8%

Over the last year, the Cash & Cash Equivalents growth was -44%. The average annual Cash & Cash Equivalents growth rates for Novo Nordisk A/S have been 4% over the past three years , 5% over the past five years , and 8% over the past ten years .

Back to Top